The annual throat preservation rate is nearly 80%, and Shanghai research was included in the International Annual Conference: Immunotherapy for locally advanced head and neck tumors | Patients | Local

Release time:Apr 13, 2024 21:41 PM

At the recent 2023 Annual Meeting of the American Society of Clinical Oncology, research from Fudan University Affiliated Cancer Hospital was quite impressive: in the field of head and neck tumors, "induction chemotherapy combined with treprizumab can be used for laryngeal preservation treatment in patients with locally advanced laryngeal/hypopharyngeal cancer. The results of the Phase II clinical trial showed a one-year laryngeal preservation rate of 79.4%." The first author of this study, abbreviated as INSIGHT, is Professor Xiaomin Qu from Fudan University Affiliated Cancer Hospital, and the corresponding authors are Professor Yu Wang and Professor Xiayun He.

It is reported that laryngeal cancer and hypopharyngeal cancer are one of the most common head and neck squamous cell carcinoma in China, with the incidence rate accounting for about 20% of head and neck squamous cell carcinoma. Due to the insidious symptoms of the disease, the patient was diagnosed later and had a poor prognosis. Previously, surgical resection was used to prolong survival. With the development of multidisciplinary comprehensive treatment, diagnostic and treatment strategies emphasize the importance of organ function preservation. Previous studies have revealed that induction chemotherapy combined with radiation therapy can be used for the treatment of related patients, but scientists have been exploring better options.

Immunotherapy represented by PD-1 inhibitors has become the standard treatment for multiple types of tumors in recent years. In the field of head and neck tumors, previous clinical studies have shown that induction chemotherapy combined with PD-1 inhibitors has a good pathological response to locally advanced head and neck tumors, but its effect on laryngeal function preservation is not yet clear. Cancer hospitals are conducting INSIGHT research to explore therapeutic effects, in order to provide scientific references for clinical diagnosis and treatment.

In the Phase II study, all participants received induction chemotherapy combined with treprizumab for three cycles, followed by postoperative radiotherapy or concurrent radiotherapy and chemotherapy depending on the situation. A total of 27 patients were included in the study. Three months after radiotherapy, it was found that the objective response rate after combined induction therapy reached 85.2%, and 23 patients achieved laryngeal function preservation, with a three-month laryngeal preservation rate of 85.2%. In terms of survival benefits, with a median follow-up of 13.5 months, the 1-year overall survival rate, 1-year progression free survival rate, and 1-year laryngeal preservation rate were 83.1%, 79.5%, and 79.4%, respectively.

Qu Xiaomin stated that for patients with locally advanced laryngeal and hypopharyngeal cancer, INSIGHT research has revealed satisfactory short-term laryngeal preservation rates and survival benefits. From this, it can be seen that induction chemotherapy combined with PD-1 inhibitors may be a potential treatment strategy for related patients, with broad clinical application prospects. It is reported that INSIGHT research has been included in the annual meeting of the American Society of Clinical Oncology, representing the widespread recognition of research results by international peers. Experts have added that INSIGHT research is still being followed up continuously, and the team surrounding the immunotherapy combination plan will conduct more and larger sample size clinical studies to verify the clinical value of the strategy and benefit more patients as soon as possible.

Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended